Company: HMDCF
Filing Date: 2025-03-19
Form Type: 20-F
Source: 0001410578-25-000377
Chunk: 648

Company: HUTCHMED (China) Ltd
Filing Date: 2025-03-19
Form: 20-F
Item: Item 16K
Chunk 648
---
000and US$43,718,000respectively.

Based on the Group’s operating plan, the existing cash and cash equivalents, short-term investments and unutilized bank borrowing facilities are considered to be sufficient to meet the cash requirements to fund planned operations and other commitments for at least the next twelve months from the issuance date of the consolidated financial statements.

2. Particulars of Principal Subsidiaries and Equity Investee

                                                                                                                                                                                 Equity interest                                                                                                          
                                                                                                                                                              Place of           attributable to                                                                                                          
                                                                                                                                                              establishment      the Group                                                                                                                
                                                                                                                                                              and                December 31,                                                                                                             
  Name                                                                                                                                                        operations         2024                  2023      Principal activities                                                                     
  Subsidiaries                                                                                                                                                                                                                                                                                            
  HUTCHMED Limited                                                                                                                                            PRC                99.75                99.75      Research, development, manufacture and commercialization of pharmaceutical products      
  HUTCHMED International Corporation                                                                                                                          US                 99.75                99.75      Provision of professional, scientific and technical support services                     
  Shanghai Hutchison Whampoa Pharmaceutical Sales Limited (formerly known as “ Hutchison Whampoa Sinopharm Pharmaceuticals (Shanghai) Company Limited ”)      PRC                50.87                50.87      Provision of sales, distribution and marketing services to pharmaceutical manufacturers  
  Hutchison Healthcare Limited                                                                                                                                PRC                100                    100      Manufacture and distribution of healthcare products                                      
  Equity investee                                                                                                                                                                                                                                                                                         
  SHPL                                                                                                                                                        PRC                50                      50      Manufacture and distribution of prescription drug products                               

F-10

Table of Contents

3. Summary of Significant Accounting Policies
Principles of Consolidation and Basis of Presentation
The accompanying consolidated financial statements reflect the accounts of the Company and all of its subsidiaries in which a controlling interest is maintained. When a subsidiary is deconsolidated from the date that control ceases, any gain or loss on the divestment of the interest sold is recognized in profit or loss. Amounts previously recognized in other comprehensive income/(loss) for the subsidiary are transferred to the consolidated statements of operations as part of the gain or loss on the divestment. All inter-company balances and transactions have been eliminated in consolidation. The consolidated financial statements have been prepared in conformity with generally accepted accounting principles in the US (“ US GAAP”).
Use of Estimates
The preparation of consolidated financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts